Belay Diagnostics wins the Palantir Buildcamp for the second year running, highlighting its advancements in molecular diagnostics and automated insurance appeals technology.
Palantir is named only as the host of the Buildcamp competition that Belay Diagnostics won for the second consecutive year on Nov. 4, 2026. The release contains no contract values, revenue figures or customer commitments tied to Palantir, so it is a routine ecosystem mention rather than a financial driver.
Belay Diagnostics has claimed its second straight win at the Palantir Buildcamp competition. The company showcased its proprietary molecular case review prototype and insurance appeals application, reinforcing its position in the cerebrospinal fluid liquid biopsy market.
The Palantir Buildcamp is a competitive event hosted by Palantir Technologies where companies demonstrate innovative applications built using Palantir's software ecosystem.
Belay Diagnostics specializes in cerebrospinal fluid (CSF) liquid biopsy testing and related molecular diagnostic technologies.